75 related articles for article (PubMed ID: 37342361)
1. Effect of dendritic cell-cytokine-induced killer cells in patients with advanced colorectal cancer combined with first-line treatment.
Xie Y; Huang L; Chen L; Lin X; Chen L; Zheng Q
World J Surg Oncol; 2017 Nov; 15(1):209. PubMed ID: 29179719
[TBL] [Abstract][Full Text] [Related]
2. The Antitumor Immunity and Tumor Responses of Chemotherapy with or without DC-CIK for Non-Small-Cell Lung Cancer in China: A Meta-Analysis of 28 Randomized Controlled Trials.
Xiao Z; Wang CQ; Zhou MH; Li NN; Sun YP; Wang YZ; Liu SY; Yu HS; Li CW; Zeng XT; Chen L; Yao XS; Feng JH
J Immunol Res; 2018; 2018():9081938. PubMed ID: 30648123
[TBL] [Abstract][Full Text] [Related]
3. Enhanced antitumor effects of DC-activated CIKs to chemotherapy treatment in a single cohort of advanced non-small-cell lung cancer patients.
Yang L; Ren B; Li H; Yu J; Cao S; Hao X; Ren X
Cancer Immunol Immunother; 2013 Jan; 62(1):65-73. PubMed ID: 22744010
[TBL] [Abstract][Full Text] [Related]
4. Use of cytokine-induced killer cell therapy in patients with colorectal cancer: a systematic review and meta-analysis.
Li CMY; Tomita Y; Dhakal B; Li R; Li J; Drew P; Price T; Smith E; Maddern GJ; Fenix KA
J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37117007
[TBL] [Abstract][Full Text] [Related]
5. Effect of autologous dendritic cell cytokine-induced killer on refractory metastatic colorectal cancer: a matched case-control comparative study.
Chang SC; Ke TW; Chen WT; Shyu WC; Jeng LB
Front Immunol; 2024; 15():1329615. PubMed ID: 38476223
[TBL] [Abstract][Full Text] [Related]
6. The Therapeutic Potential of Cytokine-Induced Killer in Patients with Cancer.
Zhong S; Zhang Y; Lu X; Meftahpour V
J Interferon Cytokine Res; 2024 Mar; 44(3):99-110. PubMed ID: 38488758
[TBL] [Abstract][Full Text] [Related]
7. Safety of dendritic cell and cytokine-induced killer (DC-CIK) cell-based immunotherapy in patients with solid tumor: a retrospective study in China.
Wang S; Song Y; Shi Q; Qiao G; Zhao Y; Zhou L; Zhao J; Jiang N; Huang H
Am J Cancer Res; 2023; 13(10):4767-4782. PubMed ID: 37970341
[TBL] [Abstract][Full Text] [Related]
8. Clinical research of genetically modified dendritic cells in combination with cytokine-induced killer cell treatment in advanced renal cancer.
Wang D; Zhang B; Gao H; Ding G; Wu Q; Zhang J; Liao L; Chen H
BMC Cancer; 2014 Apr; 14():251. PubMed ID: 24720900
[TBL] [Abstract][Full Text] [Related]
9. Blood microbiota diversity determines response of advanced colorectal cancer to chemotherapy combined with adoptive T cell immunotherapy.
Yang D; Wang X; Zhou X; Zhao J; Yang H; Wang S; Morse MA; Wu J; Yuan Y; Li S; Hobeika A; Lyerly HK; Ren J
Oncoimmunology; 2021; 10(1):1976953. PubMed ID: 34595059
[TBL] [Abstract][Full Text] [Related]
10. Cytokine-induced killer (CIK) cells, successes and challenges: report on the first international conference dedicated to the clinical translation of this unique adoptive cell immunotherapy.
Sharma A; Ren X; Rosato A; Sangiolo D; Wang Z; Tettamanti S; Zhang Y; Rettinger E; Fenix KA; Sommaggio R; Cappuzzello E; Schmidt-Wolf IGH
Cancer Immunol Immunother; 2024 Jan; 73(2):21. PubMed ID: 38279995
[TBL] [Abstract][Full Text] [Related]
11. Case report: Dendritic cell-cytokine induced killer cell therapy in subjects with chronic lymphocytic leukemia and peritoneal cancer.
Mehling B; Wu D; O'Gorman E; Sheridan D; Santora D; Mihályová R
Front Med (Lausanne); 2023; 10():1240330. PubMed ID: 37877016
[TBL] [Abstract][Full Text] [Related]
12. Correlation analysis of circulating tumor cells and Claudin-4 in breast cancer.
Chai J; Liu X; Hu X; Wang C
Pathol Oncol Res; 2023; 29():1611224. PubMed ID: 37465316
[No Abstract] [Full Text] [Related]
13. Prognostic value of pretreatment Controlling Nutritional Status score in esophageal cancer: a meta-analysis.
Lv J; Chen P; Wu J; Hu C
Pathol Oncol Res; 2023; 29():1611221. PubMed ID: 37441713
[No Abstract] [Full Text] [Related]
14. Tumor subtypes and signature model construction based on chromatin regulators for better prediction of prognosis in uveal melanoma.
Li Y; Xiong C; Wu LL; Zhang BY; Wu S; Chen YF; Xu QH; Liao HF
Pathol Oncol Res; 2023; 29():1610980. PubMed ID: 37362244
[No Abstract] [Full Text] [Related]
15. CVM-1118 (foslinanib), a 2-phenyl-4-quinolone derivative, promotes apoptosis and inhibits vasculogenic mimicry via targeting TRAP1.
Shen L; Chen YL; Huang CC; Shyu YC; Seftor REB; Seftor EA; Hendrix MJC; Chien DS; Chu YW
Pathol Oncol Res; 2023; 29():1611038. PubMed ID: 37351538
[TBL] [Abstract][Full Text] [Related]
16. Cytokine-induced killer cell treatment is superior to chemotherapy alone in esophageal cancer.
Sun J; Sun Y; Miniderima ; Wang X
Pathol Oncol Res; 2023; 29():1610710. PubMed ID: 37342361
[No Abstract] [Full Text] [Related]
17. Efficacy and safety of dendritic cells co-cultured with cytokine-induced killer cells immunotherapy for non-small-cell lung cancer.
Wang S; Wang Z
Int Immunopharmacol; 2015 Sep; 28(1):22-8. PubMed ID: 26013109
[TBL] [Abstract][Full Text] [Related]
18. Cytokine-induced killer cells/dendritic cells and cytokine-induced killer cells immunotherapy for the treatment of esophageal cancer: A meta-analysis.
Yuan X; Zhang AZ; Ren YL; Wang XL; Jiang CH; Yang L; Liu CX; Liang WH; Pang LJ; Gu WY; Li F; Hu JM
Medicine (Baltimore); 2021 Apr; 100(13):e24519. PubMed ID: 33787569
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
